Consequently, the increase in IL‐33 and the decrease in OPN in peripheral blood and tumor tissues suggested IL‐33 and OPN as potential indicators for the efficacy of the early treatment of tumors with cetuximab. This evidence concerns the gene IL33 and neoplasm.